A therepeutic method whereby an individual suspected of having an . alpha.-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human &agr-gal A, or (2) purified human . alpha.- gal A obtained from cultured, genetically modified human cells.